Genomic profiling of murine mammary tumors identifies potential personalized drug targets for p53-deficient mammary cancers

DMM Disease Models and Mechanisms

Volumn 9, Issue 7, 2016, Pages 749-757

  Pfefferle, Adam D ^a,b   Agrawal, Yash N ^b   Koboldt, Daniel C ^c   Kanchi, Krishna L ^c   Herschkowitz, Jason I ^d   Mardis, Elaine R ^c   Rosen, Jeffrey M ^e   Perou, Charles M ^a,b  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF NORTH CAROLINA   (United States)

^c WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d STATE UNIVERSITY OF NEW YORK   (United States)

^e BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

Basal like breast cancer; Exome sequencing; Genetically engineered mouse models; P53; Personalized genomics; Whole genome sequencing

Indexed keywords

CLAUDIN; CRIZOTINIB; CYCLIN DEPENDENT KINASE 4; EPIDERMAL GROWTH FACTOR RECEPTOR 2; LYSOSOME ASSOCIATED MEMBRANE PROTEIN 1; PROTEIN P53; SCATTER FACTOR RECEPTOR; TRANSCRIPTION FACTOR FOXP2; PYRAZOLE DERIVATIVE; PYRIDINE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BCAR3 GENE; BREAST CANCER; CANCER STEM CELL; DDX39B GENE; DNA MICROARRAY; DNAJC8 GENE; EXOME; GENE DOSAGE; GENE EXPRESSION; GENETIC VARIATION; GLCCI1 GENE; GLP1R GENE; HUMAN; HUMAN CELL; MAD2L1 GENE; MOUSE; MPP7 GENE; NDUFC2 GENE; NONHUMAN; PERSONALIZED MEDICINE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RNF11 GENE; SFPQ GENE; SMAP1 GENE; SOMATIC MUTATION; SRGAP2 GENE; VPS72 GENE; ANIMAL; BAGG ALBINO MOUSE; BREAST TUMOR; CHROMOSOME; COPY NUMBER VARIATION; DEFICIENCY; EXPERIMENTAL MAMMARY NEOPLASM; FEMALE; GENE EXPRESSION PROFILING; GENETICS; METABOLISM; MOLECULARLY TARGETED THERAPY; PATHOLOGY;

ANIMALS; BREAST NEOPLASMS; CHROMOSOMES, MAMMALIAN; DNA COPY NUMBER VARIATIONS; FEMALE; GENE EXPRESSION PROFILING; HUMANS; MAMMARY NEOPLASMS, ANIMAL; MICE, INBRED BALB C; MOLECULAR TARGETED THERAPY; PRECISION MEDICINE; PYRAZOLES; PYRIDINES; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84977559953     PISSN: 17548403     EISSN: 17548411     Source Type: Journal    
DOI: 10.1242/dmm.025239     Document Type: Article

References (55)

1. Agoulnik, I. U., Hodgson, M. C., Bowden, W. A. And Ittmann, M. M. (2011). INPP4B: the new kid on the PI3K block. Oncotarget 2, 321-328.
2. Bennett, C. N., Tomlinson, C. C., Michalowski, A. M., Chu, I. M., Luger, D., Mittereder, L. R., Aprelikova, O., Shou, J., Piwinica-Worms, H., Caplen, N. J. et al. (2012). Cross-species genomic and functional analyses identify a combination therapy using a CHK1 inhibitor and a ribonucleotide reductase inhibitor to treat triple-negative breast cancer. Breast Cancer Res. 14, R109.
3. Bieging, K. T., Mello, S. S. And Attardi, L. D. (2014). Unravelling mechanisms of p53-mediated tumour suppression. Nat. Rev. Cancer 14, 359-370.
4. Brosh, R. And Rotter, V. (2009). When mutants gain new powers: news from the mutant p53 field. Nat. Rev. Cancer. 9, 701-713.
5. Bullock, A. N. And Fersht, A. R. (2001). Rescuing the function of mutant p53. Nat. Rev. Cancer 1, 68-76.
6. Cancer Genome Atlas Network. (2012). Comprehensive molecular portraits of human breast tumours. Nature 490, 61-70.
7. Carey, L., Winer, E., Viale, G., Cameron, D. And Gianni, L. (2010). Triple-negative breast cancer: disease entity or title of convenience? Nat. Rev. Clin. Oncol. 7, 683-692.
8. Chen, L. C., Manjeshwar, S., Lu, Y., Moore, D., Ljung, B. M., Kuo, W. L., Dairkee, S. H., Wernick, M., Collins, C. And Smith, H. S. (1998). The human homologue for the Caenorhabditis elegans cul-4 gene is amplified and overexpressed in primary breast cancers. Cancer Res. 58, 3677-3683.
9. Curigliano, G. (2012). New drugs for breast cancer subtypes: targeting driver pathways to overcome resistance. Cancer Treat. Rev. 38, 303-310.
10. Curigliano, G. And Goldhirsch, A. (2011). The triple-negative subtype: new ideas for the poorest prognosis breast cancer. J. Natl. Cancer Inst. Monogr. 2011, 108-110.
11. Curtis, C., Shah, S. P., Chin, S. F., Turashvili, G., Rueda, O. M., Dunning, M. J., Speed, D., Lynch, A. G., Samarajiwa, S., Yuan, Y. et al. (2012). The genomic and transcriptomic architecture of 2, 000 breast tumours reveals novel subgroups. Nature 486, 346-352.
12. Diéras, V., Campone, M., Yardley, D. A., Romieu, G., Valero, V., Isakoff, S. J., Koeppen, H., Wilson, T. R., Xiao, Y., Shames, D. S. et al. (2015). Randomized, phase II, placebo-controlled trial of onartuzumab and/or bevacizumab in combination with weekly paclitaxel in patients with metastatic triple-negative breast cancer. Ann. Oncol. 26, 1904-1910.
13. Duncan, J. S., Whittle, M. C., Nakamura, K., Abell, A. N., Midland, A. A., Zawistowski, J. S., Johnson, N. L., Granger, D. A., Jordan, N. V., Darr, D. B. et al. (2012). Dynamic reprogramming of the kinome in response to targeted MEK inhibition in triple-negative breast cancer. Cell. 149, 307-321.
14. Gastaldi, S., Comoglio, P. M. And Trusolino, L. (2010). The Met oncogene and basal-like breast cancer: another culprit to watch out for? Breast Cancer Res. 12, 208.
15. Gupta, A., Yang, L.-X. And Chen, L.-C. (2002). Study of the G2/M cell cycle checkpoint in irradiated mammary epithelial cells overexpressing Cul-4A gene. Int. J. Radiat. Oncol. Biol. Phys. 52, 822-830.
16. Hanel, W. And Moll, U. M. (2012). Links between mutant p53 and genomic instability. J. Cell. Biochem. 113, 433-439.
17. Harrell, J. C., Prat, A., Parker, J. S., Fan, C., He, X., Carey, L., Anders, C., Ewend, M. And Perou, C. M. (2012). Genomic analysis identifies unique signatures predictive of brain, lung, and liver relapse. Breast Cancer Res. Treat. 132, 523-535.
18. Herschkowitz, J. I., Zhao, W., Zhang, M., Usary, J., Murrow, G., Edwards, D., Knezevic, J., Greene, S. B., Darr, D., Troester, M. A. et al. (2012). Comparative oncogenomics identifies breast tumors enriched in functional tumor-initiating cells. Proc. Natl. Acad. Sci. USA. 109, 2778-2783.
19. Ho-Yen, C. M., Jones, J. L. And Kermorgant, S. (2015). The clinical and functional significance of c-Met in breast cancer: a review. Breast Cancer Res. 17, 52.
20. Hynes, N. E. And Lane, H. A. (2005). ERBB receptors and cancer: the complexity of targeted inhibitors. Nat. Rev. Cancer. 5, 341-354.
21. Jacks, T., Remington, L., Williams, B. O., Schmitt, E. M., Halachmi, S., Bronson, R. T. And Weinberg, R. A. (1994). Tumor spectrum analysis in p53-mutant mice. Curr. Biol. 4, 1-7.
22. Jackson, S. And Xiong, Y. (2009). CRL4s: the CUL4-RING E3 ubiquitin ligases. Trends Biochem. Sci. 34, 562-570.
23. Jerry, D. J., Kittrell, F. S., Kuperwasser, C., Laucirica, R., Dickinson, E. S., Bonilla, P. J., Butel, J. S. And Medina, D. (2000). A mammary-specific model demonstrates the role of the p53 tumor suppressor gene in tumor development. Oncogene. 19, 1052-1058.
24. Jordan, V. C. (2003). Tamoxifen: a most unlikely pioneering medicine. Nat. Rev. Drug Discov. 2, 205-213.
25. Kannan, N., Huda, N., Tu, L., Droumeva, R., Aubert, G., Chavez, E., Brinkman, R. R., Lansdorp, P., Emerman, J., Abe, S. et al. (2013). The luminal progenitor compartment of the normal human mammary gland constitutes a unique site of telomere dysfunction. Stem Cell Rep. 1, 28-37.
26. Knight, J. F., Lesurf, R., Zhao, H., Pinnaduwage, D., Davis, R. R., Saleh, S. M. I., Zuo, D., Naujokas, M. A., Chughtai, N., Herschkowitz, J. I. et al. (2013). Met synergizes with p53 loss to induce mammary tumors that possess features of claudin-low breast cancer. Proc. Natl. Acad. Sci. USA. 110, E1301-E1310.
27. Koboldt, D. C., Zhang, Q., Larson, D. E., Shen, D., Mclellan, M. D., Lin, L., Miller, C. A., Mardis, E. R., Ding, L. And Wilson, R. K. (2012). VarScan 2: somatic mutation and copy number alteration discovery in cancer by exome sequencing. Genome Res. 22, 568-576.
28. Koh, J. L. Y., Brown, K. R., Sayad, A., Kasimer, D., Ketela, T. And Moffat, J. (2012). COLT-Cancer: functional genetic screening resource for essential genes in human cancer cell lines. Nucleic Acids Res. 40, D957-D963.
29. Lim, E., Vaillant, F., Wu, D., Forrest, N. C., Pal, B., Hart, A. H., Asselin-Labat, M.-L., Gyorki, D. E., Ward, T., Partanen, A. et al. (2009). Aberrant luminal progenitors as the candidate target population for basal tumor development in BRCA1 mutation carriers. Nat. Med. 15, 907-913.
30. Marcotte, R., Brown, K. R., Suarez, F., Sayad, A., Karamboulas, K., Krzyzanowski, P. M., Sircoulomb, F., Medrano, M., Fedyshyn, Y., Koh, J. L. Y. et al. (2012). Essential gene profiles in breast, pancreatic, and ovarian cancer cells. Cancer Discov. 2, 172-189.
31. Murphy, K. L. And Rosen, J. M. (2000). Mutant p53 and genomic instability in a transgenic mouse model of breast cancer. Oncogene. 19, 1045-1051.
32. Murphy, K. L., Dennis, A. P. And Rosen, J. M. (2000). A gain offunction p53 mutant promotes both genomic instability and cell survival in a novel p53-null mammary epithelial cell model. FASEB J. 14, 2291-2302.
33. Parker, J. S., Mullins, M., Cheang, M. C. U., Leung, S., Voduc, D., Vickery, T., Davies, S., Fauron, C., He, X., Hu, Z. et al. (2009). Supervised risk predictor of breast cancer based on intrinsic subtypes. J. Clin. Oncol. 27, 1160-1167.
34. Perou, C. M., Sørlie, T., Eisen, M. B., Van De Rijn, M., Jeffrey, S. S., Rees, C. A., Pollack, J. R., Ross, D. T., Johnsen, H., Akslen, L. A. et al. (2000). Molecular portraits of human breast tumours. Nature. 406, 747-752.
35. Pfefferle, A. D., Herschkowitz, J. I., Usary, J., Harrell, J. C., Spike, B. T., Adams, J. R., Torres-Arzayus, M. I., Brown, M., Egan, S. E., Wahl, G. M. et al. (2013). Transcriptomic classification of genetically engineered mouse models of breast cancer identifies human subtype counterparts. Genome Biol. 14, R125.
36. Pfefferle, A. D., Spike, B. T., Wahl, G. M. And Perou, C. M. (2015). Luminal progenitor and fetal mammary stem cell expression features predict breast tumor responseto neoadjuvant chemotherapy. Breast Cancer Res. Treat. 149, 425-437.
37. Prat, A. And Perou, C. M. (2011). Deconstructing the molecular portraits of breast cancer. Mol. Oncol. 5, 5-23.
38. Prat, A., Parker, J. S., Karginova, O., Fan, C., Livasy, C., Herschkowitz, J. I., He, X. And Perou, C. M. (2010). Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancer. Breast Cancer Res. 12, R68.
39. Prat, A., Karginova, O., Parker, J. S., Fan, C., He, X., Bixby, L., Harrell, J. C., Roman, E., Adamo, B., Troester, M. et al. (2013). Characterization of cell lines derived from breast cancers and normal mammary tissues for the study of the intrinsic molecular subtypes. Breast Cancer Res. Treat. 142, 237-255.
40. Roberts, P. J., Bisi, J. E., Strum, J. C., Combest, A. J., Darr, D. B., Usary, J. E., Zamboni, W. C., Wong, K.-K., Perou, C. M. And Sharpless, N. E. (2012a). Multiple roles of cyclin-dependent kinase 4/6 inhibitors in cancer therapy. J. Natl. Cancer Inst. 104, 476-487.
41. Roberts, P. J., Usary, J. E., Darr, D. B., Dillon, P. M., Pfefferle, A. D., Whittle, M. C., Duncan, J. S., Johnson, S. M., Combest, A. J., Jin, J. et al. (2012b). Combined PI3K/mTOR and MEK inhibition provides broad antitumor activity in faithful murine cancer models. Clin. Cancer Res. 18, 5290-5303.
42. Saucedo-Cuevas, L. P., Ruppen, I., Ximénez-Embún, P., Domingo, S., Gayarre, J., Muñoz, J., Silva, J. M., García, M. J. And Benítez, J. (2014). CUL4A contributes to the biology of basal-like breast tumors through modulation of cell growth and antitumor immune response. Oncotarget. 5, 2330-2343.
43. Schvartzman, J.-M., Sotillo, R. And Benezra, R. (2010). Mitotic chromosomal instability and cancer: mouse modelling of the human disease. Nat. Rev. Cancer. 10, 102-115.
44. Sharma, P. And Nag, A. (2014). CUL4A ubiquitin ligase: a promising drug target for cancer and other human diseases. Open Biol. 4, 130217.
45. Shaw, A. T., Yasothan, U. And Kirkpatrick, P. (2011). Crizotinib. Nat. Rev. Drug Discov. 10, 897-898.
46. Silva, G. O., He, X., Parker, J. S., Gatza, M. L., Carey, L. A., Hou, J. P., Moulder, S. L., Marcom, P. K., Ma, J., Rosen, J. M. et al. (2015). Cross-species DNA copy number analyses identifies multiple 1q21-q23 subtype-specific driver genes for breast cancer. Breast Cancer Res. Treat. 152, 347-356.
47. Smolen, G. A., Muir, B., Mohapatra, G., Barmettler, A., Kim, W. J., Rivera, M. N., Haserlat, S. M., Okimoto, R. A., Kwak, E., Dahiya, S. et al. (2006). Frequent met oncogene amplification in a Brca1/Trp53 mouse model of mammary tumorigenesis. Cancer Res. 66, 3452-3455.
48. Solomon, B. J., Mok, T., Kim, D.-W., Wu, Y.-L., Nakagawa, K., Mekhail, T., Felip, E., Cappuzzo, F., Paolini, J., Usari, T. et al. (2014). First-line crizotinib versus chemotherapy in ALK-positive lung cancer. N Engl. J. Med. 371, 2167-2177.
49. Sotillo, R., Hernando, E., Díaz-Rodríguez, E., Teruya-Feldstein, J., Cordon-Cardo, C., Lowe, S. W. And Benezra, R. (2007). Mad2 overexpression promotes aneuploidy and tumorigenesis in mice. Cancer Cell. 11, 9-23.
50. Spigel, D. R., Ervin, T. J., Ramlau, R. A., Daniel, D. B., Goldschmidt, J. H., Jr., Blumenschein, G. R., Jr., Krzakowski, M. J., Robinet, G., Godbert, B., Barlesi, F. et al. (2013). Randomized phase II trial of Onartuzumabin combination with erlotinib in patients with advanced non-small-cell lung cancer. J. Clin. Oncol. 31, 4105-4114.
51. Tusher, V. G., Tibshirani, R. And Chu, G. (2001). Significance analysis of microarrays applied to the ionizing radiation response. Proc. Natl. Acad. Sci. USA. 98, 5116-5121.
52. Usary, J., Zhao, W., Darr, D., Roberts, P. J., Liu, M., Balletta, L., Karginova, O., Jordan, J., Combest, A., Bridges, A. et al. (2013). Predicting drug responsiveness in human cancers using genetically engineered mice. Clin. Cancer Res. 19, 4889-4899.
53. Visvader, J. E. (2009). Keeping abreast of the mammary epithelial hierarchy and breast tumorigenesis. Genes Dev. 23, 2563-2577.
54. Weigman, V. J., Chao, H.-H., Shabalin, A. A., He, X., Parker, J. S., Nordgard, S. H., Grushko, T., Huo, D., Nwachukwu, C., Nobel, A. et al. (2012). Basal-like Breast cancer DNA copy number losses identify genes involved in genomic instability, response to therapy, and patient survival. Breast Cancer Res. Treat. 133, 865-880.
55. Xu, K., Usary, J., Kousis, P. C., Prat, A., Wang, D.-Y., Adams, J. R., Wang, W., Loch, A. J., Deng, T., Zhao, W. et al. (2012). Lunatic fringe deficiency cooperates with the Met/Caveolin gene amplicon to induce basal-like breast cancer. Cancer Cell. 21, 626-641.